Roche's Mircera gets FDA approval

ZURICH , Switzerland The Food and Drug Administration has approved Roche Holdings’ new drug Mircera, which is used for the treatment of anemia associated with chronic renal failure in adults, including patients on dialysis and patients not on dialysis, according to money.cnn.com

The drug though still cannot be launched on the market because of a patent infringement case the company was involved in with another biotech company Amgen. Amgen claims Mircera infringes 11 of its patents and a federal court in Boston last month agreed that Mircera did infringe the patents.

Roche said it is still evaluating its legal options including the possibility of an appeal.